ESPOSITO, MARIA
 Distribuzione geografica
Continente #
NA - Nord America 2.126
EU - Europa 1.137
AS - Asia 331
OC - Oceania 2
Totale 3.596
Nazione #
US - Stati Uniti d'America 2.121
IE - Irlanda 698
CN - Cina 290
UA - Ucraina 150
DE - Germania 90
FR - Francia 56
SE - Svezia 48
IT - Italia 33
GB - Regno Unito 18
FI - Finlandia 16
TR - Turchia 16
BE - Belgio 13
SG - Singapore 8
IN - India 6
VN - Vietnam 6
CA - Canada 3
HU - Ungheria 3
TW - Taiwan 3
CR - Costa Rica 2
ES - Italia 2
NL - Olanda 2
PT - Portogallo 2
RS - Serbia 2
AT - Austria 1
AU - Australia 1
BN - Brunei Darussalam 1
EE - Estonia 1
JP - Giappone 1
LT - Lituania 1
LU - Lussemburgo 1
NZ - Nuova Zelanda 1
Totale 3.596
Città #
Dublin 696
Jacksonville 613
Chandler 469
Lawrence 102
Princeton 102
Nanjing 75
New York 72
Ann Arbor 71
Wilmington 66
Beijing 57
Dearborn 55
Boardman 33
Shenyang 24
Los Angeles 22
Nanchang 22
Jinan 18
Hebei 17
Jiaxing 16
Ashburn 15
Brussels 13
San Mateo 12
Izmir 11
Des Moines 10
Changsha 9
Lappeenranta 8
Norwalk 8
Houston 7
Kunming 7
Ningbo 7
Seattle 7
Woodbridge 7
Mountain View 6
Rome 6
Tianjin 6
Dong Ket 5
Milan 5
Zhengzhou 5
Fremont 4
Pune 4
Singapore 4
Budapest 3
Fairfield 3
Hefei 3
Helsinki 3
Menlo Park 3
Redwood City 3
Taizhou 3
Aci Catena 2
Bremen 2
Chicago 2
Falls Church 2
Guangzhou 2
Haikou 2
Hangzhou 2
Hyderabad 2
L'aquila 2
Lanzhou 2
London 2
Madrid 2
Niš 2
Olbia 2
Paris 2
San José 2
Taipei 2
Tappahannock 2
Amsterdam 1
Ashington 1
Auburn Hills 1
Auckland 1
Bandar Seri Begawan 1
Baotou 1
Bologna 1
Bridge 1
Chengdu 1
Dornelas 1
Frankfurt am Main 1
Hanoi 1
Istanbul 1
Lanciano 1
Las Vegas 1
Lisbon 1
Luxembourg 1
Melbourne 1
Monmouth Junction 1
Mont-Saint-Hilaire 1
New Orleans 1
Pescara 1
Phoenix 1
Prineville 1
Redmond 1
Richmond 1
Saint Louis 1
Shanghai 1
Shaoxing 1
Taiyuan 1
Tallinn 1
Tokyo 1
Verona 1
Vienna 1
Washington 1
Totale 2.788
Nome #
Frequency of melanocytic nevi in psoriatic patients is related to treatment and not to disease severity 71
A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy 68
Muir-Torre syndrome with fatal outcome 66
Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment. 62
Interobserver agreement on dermoscopic features of pigmented basal cell carcinoma 54
Dermatiti da Piogeni o Piodermiti 54
Treatment of erytrodermic psoriasis with etanercept 54
Interobserver agreement on dermoscopic features of pigmented basal cell carcinoma 53
Systemic treatment: Ciclosporin 52
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic 49
Influence and variation of the body mass index (BMI) in patients treated with etanercept for plaque-type psoriasis 47
Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study 46
Involvement of Ig heavy chain HS1,2-A enhancer*2 allele in dermatitis herpetiformis, plaque psoriasis and psoriatic arthritis 45
Efficacy and safety of infliximab in teh treatment of severe or arthropathic psoriasis: preliminary results 44
Quality of life 43
CONTINUOUS TREATMENT OF PLAQUE-TYPE PSORIASIS WITH ETANERCEPT: AN OBSERVATIONAL LONG-TERM EXPERIENCE 43
Association between psoriasis and periodontitis, and efficacy of anti-TNF-α therapy: a case series 43
Clinical Variants 42
Treatment of early stage mycosis fungoides with topical bexarotene 42
Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis 42
Clinical applications of PPI-TT guidelines on transitioning therapies in the treatment of moderate to severe psoriasis: an expert opinion of central Italy dermatologists 41
Treatment of erythrodermic psoriasis with etanercept 41
Clinical markers predictive of primary inefficacy: a "real life" retrospective study in psoriatic patients treated with etanercept. 41
Combination therapy with etanercept in psoriasis: Retrospective analysis of efficacy and safety outcomes from real-life practice 40
Use of etanercept in patients with psoriasis and concomitant hepatitis C infection 39
An Italian study on psoriasis and depression 39
Differences in percutaneous absorption in normal and atopic dermatitis skin in relation to molecular weigh. 38
High-dose initiation of etanercept in plaque psoriasis and psoriatic arthritis: an italian experience 38
UVA1 Laser in the Treatment of Vitiligo 38
Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis 38
Cutaneous body image in psoriasis: The role of attachment style and alexithymia 38
UVB 308 nm XeCl excimer laser for mycosis fungoides 37
Topical corticotherapy: the expert's opinion 37
Long-lasting remission of pemphigus vulgaris treated with rituximab 37
Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience 37
Dermatiti da piogeni o piodermiti 36
Association between Psoriasis and haplotypes of the IgH 3' Regulatory Region 1 36
Unresponsiveness to etanercept: is there a common phenotipical profile of patients? 36
Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. 36
Betamethasone valerate dressing is non-inferior to calcipotriol-betamethasone dipropionate ointment in the treatment of patients with mild-to-moderate chronic plaque psoriasis: results of a randomized assessor-blinded multicentre trial 36
A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis 36
Consensus on the place in therapy of TNF-α inhibitors in the treatment of patients with chronic plaque psoriasis 36
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study 36
Resolution of idiopathic recurrent pericarditis in a psoriatic arthritis patient treated with etanercept 35
Treatment adherence to different etanercept regimens, continuous vs. intermittent, in patients affected by plaque-type psoriasis 35
Some considerations about the importance of alliance between patients and dermatologists in psoriasis 35
A case of generalized pustular psoriasis and arthritis treated with ixekizumab 35
Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis 34
Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. 34
Haplotypes associated with alleles of the immunoglobulin heavy chain enhancer HS1,2 of the 3¢ regulatory region in patients with psor- iatic arthritis 34
Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis. 34
Etanercept, childhood and long-term safety: a case of five years treatment. 33
Long-term efficacy of etanercept in hidradenitis suppurativa. 33
PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre study 33
Histopathology of the skin in rheumatic diseases 33
Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice 33
Survival rate of antitumour necrosis factor- treatments for psoriasis in routine dermatological practice: a multicentre observational study 32
Long-term efficacy of infliximab therapy in plaque psoriasis and arthropathic psoriasis 32
INFLUENCE AND VARIATION OF THE BODY MASS INDEX IN PATIENTS TREATED WITH ETANERCEPT FOR PLAQUE-TYPE PSORIASIS 32
Psoriasis target therapy: ustekinumab 32
Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series 32
Morbid obesity and psoriasis: Disease remission after laparoscopic sleeve gastrectomy 32
Trimethoprim-sulfamethoxazole induced erythrodermic psoriasis 31
Treatment of vitiligo with the 308 nm excimer laser 31
Potential Role of Cytochrome c and Tryptase in Psoriasis and Psoriatic Arthritis Pathogenesis: Focus on Resistance to Apoptosis and Oxidative Stress 31
Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: A 24-week real-life experience 31
High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: Efficacy, safety and impact on patients' quality of life 30
Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management 30
Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients' clinical characteristics leading to disease relapse 30
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis 30
Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis 30
A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis 30
Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study 30
Effect of anti tumor necrosis factor-alpha therapies on body composition in patients with psoriasis 29
Entecavir and intermittent etanercept therapy in a patient with concurrent hepatitis B virus infection and psoriasis 29
Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-centre, observational, retrospective, real-life study 29
Psoriasis and its management in women of childbearing age: Tools to increase awareness in dermatologists and patients 29
Depressive symptoms and insecure attachment predict disability and quality of life in psoriasis independently from disease severity 29
Efficacy and Safety of Etanercept in Psoriasis after Switching from Other Treatments An Observational Study 28
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy 27
Effects of TNF-α inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients 27
Satisfaction and attitudes toward systemic treatments for psoriasis: A cross-sectional study 27
Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32-week real-world experience during the COVID-19 pandemic 26
The role of insomnia in the vulnerability to depressive and anxiety symptoms in atopic dermatitis adult patients 25
The therapeutic advantages on BMV plaster in chronic plaque psoriasis. Results from a new european multicentric study 25
Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis 25
Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: A retrospective study 25
Increased frequency of Ig heavy-chain HS1,2-A enhancer *2 allele in dermatitis herpetiformis, plaque psoriasis, and psoriatic arthritis 25
Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections 25
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations 25
From patients' needs to treatment outcomes in psoriasis: Results from the 'pSORRIDI' experience 24
Long-term treatment with etanercept monotherapy in a hemodialyzed patient with moderate-to-severe plaque-type psoriasis and psoriatic arthritis 24
Omalizumab for chronic spontaneous urticaria in “complex” patients: Data from real-life clinical practice 24
Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy 24
Nail and enthesis assessment in patients with psoriatic disease by high frequency ultrasonography: findings from a single-centre cross-sectional study 23
Long-term experience with etanercept in psoriatic arthritis patients: A 3-year observational study 23
Etanercept at different dosages in the treatment of generalized pustular psoriasis: A case series 22
Treatment of severe psoriasis during pregnancy and breastfeeding: A therapeutic challenging case 22
Risk of infections in psoriasis: assessment and challenges in daily management 21
Treatment adherence with diclofenac 3% gel among patients with multiple actinic keratoses: an integrated low-intensity intervention program versus standard-of-care 20
Totale 3.536
Categoria #
all - tutte 19.210
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.210


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201916 0 0 0 0 0 0 0 0 0 0 0 16
2019/2020843 200 9 73 24 18 93 176 35 101 27 6 81
2020/2021569 6 77 3 80 80 6 104 5 95 6 94 13
2021/2022334 7 4 19 11 24 4 3 25 66 4 37 130
2022/20231.613 121 66 15 139 98 133 5 99 840 10 58 29
2023/2024314 59 25 35 27 25 88 4 7 0 22 7 15
Totale 3.747